NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $0.09. The specialty pharmaceutical company earned $13.93 million during the quarter, compared to analyst estimates of $14.36 million. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 analysts have issued 12 month target prices for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $15.67 in the next twelve months. This suggests a possible upside of 179.3% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

News coverage about ADMS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 31st total of 1,850,000 shares. Based on an average daily trading volume, of 641,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 10.7% of the shares of the company are sold short. View Adamas Pharmaceuticals' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Agile Therapeutics (AGRX), Amarin (AMRN), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL) and Abeona Therapeutics (ABEO).

Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (2.26%), Emerald Mutual Fund Advisers Trust (2.00%), State Street Corp (1.51%), Deltec Asset Management LLC (1.43%), Panagora Asset Management Inc. (1.08%) and Renaissance Technologies LLC (1.05%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Emerald Mutual Fund Advisers Trust, Jane Street Group LLC, Emerald Advisers LLC and Bank of New York Mellon Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

ADMS stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Renaissance Technologies LLC, DCF Advisers LLC, Virtu Financial LLC, Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Adamas Pharmaceuticals.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $5.61.